Edgestream Partners L.P. Increases Holdings in Certara, Inc. (NASDAQ:CERT)

Edgestream Partners L.P. boosted its position in Certara, Inc. (NASDAQ:CERT - Free Report) by 140.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 365,708 shares of the company's stock after buying an additional 213,549 shares during the period. Edgestream Partners L.P. owned approximately 0.23% of Certara worth $3,895,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Atria Investments Inc boosted its holdings in shares of Certara by 21.6% in the 3rd quarter. Atria Investments Inc now owns 19,743 shares of the company's stock valued at $231,000 after acquiring an additional 3,501 shares during the last quarter. TimesSquare Capital Management LLC grew its position in Certara by 3.1% during the 3rd quarter. TimesSquare Capital Management LLC now owns 956,655 shares of the company's stock worth $11,202,000 after purchasing an additional 29,090 shares during the period. Versor Investments LP purchased a new stake in shares of Certara in the third quarter worth about $162,000. Geneva Capital Management LLC raised its position in Certara by 0.7% during the third quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company's stock valued at $64,525,000 after acquiring an additional 37,392 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. lifted its holdings in Certara by 6.8% in the third quarter. Oppenheimer Asset Management Inc. now owns 211,224 shares of the company's stock valued at $2,473,000 after acquiring an additional 13,500 shares during the period. Institutional investors and hedge funds own 73.96% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. William Blair reiterated a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Stephens reissued an "overweight" rating and set a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. TD Cowen started coverage on Certara in a research note on Thursday, February 27th. They issued a "buy" rating and a $16.00 price target for the company. Finally, Barclays upped their price target on Certara from $12.00 to $13.00 and gave the stock an "equal weight" rating in a report on Friday, February 28th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $15.83.

Certara Price Performance

CERT traded up $0.11 on Wednesday, hitting $11.01. 1,143,537 shares of the company's stock were exchanged, compared to its average volume of 988,352. Certara, Inc. has a fifty-two week low of $9.41 and a fifty-two week high of $19.29. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of -55.05, a P/E/G ratio of 9.29 and a beta of 1.60. The firm has a 50-day moving average price of $12.58 and a 200-day moving average price of $11.58. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.